|
1
|
van den Berg E and Dijkhuizen T:
Classification of renal cell cancer based on (cyto)genetic
analysis. Contrib Nephrol. 128:51–61. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Capitanio U and Montorsi F: Renal cancer.
Lancet. 387:894–906. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zimmerman AL and Wu S: MicroRNAs, cancer
and cancer stem cells. Cancer Lett. 300:10–19. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tutar Y: miRNA and cancer; Computational
and experimental approaches. Curr Pharm Biotechnol. 15:4292014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gulei D, Magdo L, Jurj A, Raduly L,
Cojocneanu-Petric R, Moldovan A, Moldovan C, Florea A, Pasca S, Pop
LA, et al: The silent healer: miR-205-5p up-regulation inhibits
epithelial to mesenchymal transition in colon cancer cells by
indirectly up-regulating E-cadherin expression. Cell Death Dis.
9:662018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shao P, Qu WK, Wang CY, Tian Y, Ye ML, Sun
DG, Sui JD, Wang LM, Fan R and Gao ZM: MicroRNA-205-5p regulates
the chemotherapeutic resistance of hepatocellular carcinoma cells
by targeting PTEN/JNK/ANXA3 pathway. Am J Transl Res. 9:4300–4307.
2017.PubMed/NCBI
|
|
9
|
Yamada Y, Nishikawa R, Kato M, Okato A,
Arai T, Kojima S, Yamazaki K, Naya Y, Ichikawa T and Seki N:
Regulation of HMGB3 by antitumor miR-205-5p inhibits
cancer cell aggressiveness and is involved in prostate cancer
pathogenesis. J Hum Genet. 63:195–205. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li L and Li S: miR-205-5p inhibits cell
migration and invasion in prostatic carcinoma by targeting ZEB1.
Oncol Lett. 16:1715–1721. 2018.PubMed/NCBI
|
|
11
|
Shi X, Xiao L, Mao X, He J, Ding Y, Huang
J, Peng C and Xu Z: miR-205-5p mediated downregulation of PTEN
contributes to cisplatin resistance in C13K human ovarian cancer
cells. Front Genet. 9:5552018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Edge SB and Compton CC: The American joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2−ΔΔCT method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gonzalez DM and Medici D: Signaling
mechanisms of the epithelial-mesenchymal transition. Sci Signal.
7:re82014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Rodriguez-Vida A, Hutson TE, Bellmunt J
and Strijbos MH: New treatment options for metastatic renal cell
carcinoma. ESMO Open. 2:e0001852017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Duran I, Lambea J, Maroto P,
González-Larriba JL, Flores L, Granados-Principal S, Graupera M,
Sáez B, Vivancos A and Casanovas O: Resistance to targeted
therapies in renal cancer: The importance of changing the mechanism
of action. Target Oncol. 12:19–35. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yu R, Yu BX, Chen JF, Lv XY, Yan ZJ, Cheng
Y and Ma Q: Anti-tumor effects of Atractylenolide I on bladder
cancer cells. J Exp Clin Cancer Res. 35:402016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang C, Cai L, Liu J, Wang G, Li H, Wang
X, Xu W, Ren M, Feng L, Liu P, et al: MicroRNA-30a-5p inhibits the
growth of renal cell carcinoma by modulating GRP78 expression. Cell
Physiol Biochem. 43:2405–2419. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bhat NS, Colden M, Dar AA, Saini S, Arora
P, Shahryari V, Yamamura S, Tanaka Y, Kato T, Majid S, et al:
MicroRNA-720 regulates E-cadherin-αE-catenin complex and
promotes renal cell carcinoma. Mol Cancer Ther. 16:2840–2848. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu W, Li H, Wang Y, Zhao X, Guo Y, Jin J
and Chi R: MiR-30b-5p functions as a tumor suppressor in cell
proliferation, metastasis and epithelial-to-mesenchymal transition
by targeting G-protein subunit α−13 in renal cell
carcinoma. Gene. 626:275–281. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nagai H, Hasegawa S, Uchida F, Terabe T,
Ishibashi Kanno N, Kato K, Yamagata K, Sakai S, Kawashiri S, et al:
MicroRNA-205-5p suppresses the invasiveness of oral squamous cell
carcinoma by inhibiting TIMP2 expression. Int J Oncol. 52:841–850.
2018.PubMed/NCBI
|
|
22
|
Jiang M, Zhong T, Zhang W, Xiao Z, Hu G,
Zhou H and Kuang H: Reduced expression of miR-205-5p promotes
apoptosis and inhibits proliferation and invasion in lung cancer
A549 cells by upregulation of ZEB2 and downregulation of erbB3. Mol
Med Rep. 15:3231–3238. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Fulda S: Therapeutic opportunities based
on caspase modulation. Semin Cell Dev Biol. 82:150–157. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kale J, Osterlund EJ and Andrews DW: BCL-2
family proteins: Changing partners in the dance towards death. Cell
Death Differ. 25:65–80. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dahmke IN, Backes C, Rudzitis-Auth J,
Laschke MW, Leidinger P, Menger MD, Meese E and Mahlknecht U:
Curcumin intake affects miRNA signature in murine melanoma with
mmu-miR-205-5p most significantly altered. PLoS One. 8:e811222013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brabletz T: EMT and MET in metastasis:
Where are the cancer stem cells? Cancer Cell. 22:699–701. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Brabletz T, Kalluri R, Nieto MA and
Weinberg RA: EMT in cancer. Nat Rev Cancer. 18:128–134. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kraljevic Pavelic S, Sedic M, Bosnjak H,
Spaventi S and Pavelic K: Metastasis: New perspectives on an old
problem. Mol Cancer. 10:222011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Elgamal OA, Park JK, Gusev Y,
Azevedo-Pouly AC, Jiang J, Roopra A and Schmittgen TD: Tumor
suppressive function of mir-205 in breast cancer is linked to HMGB3
regulation. PLoS One. 8:e764022013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
LoRusso PM: Inhibition of the
PI3K/AKT/mTOR pathway in solid tumors. J Clin Oncol. 34:3803–3815.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Akbani R, Ng PK, Werner HM, Shahmoradgoli
M, Zhang F, Ju Z, Liu W, Yang JY, Yoshihara K, Li J, et al: A
pan-cancer proteomic perspective on The Cancer Genome Atlas. Nat
Commun. 5:38872014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Porta C, Paglino C and Mosca A: Targeting
PI3K/Akt/mTOR signaling in cancer. Front Oncol. 4:642014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Xu X, Wu J, Li S, Hu Z, Xu X, Zhu Y, Liang
Z, Wang X, Lin Y, Mao Y, et al: Downregulation of microRNA-182-5p
contributes to renal cell carcinoma proliferation via activating
the AKT/FOXO3a signaling pathway. Mol Cancer. 13:1092014.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Lian JH, Wang WH, Wang JQ, Zhang YH and Li
Y: MicroRNA-122 promotes proliferation, invasion and migration of
renal cell carcinoma cells through the PI3K/Akt signaling pathway.
Asian Pac J Cancer Prev. 14:5017–5021. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ruan GX and Kazlauskas A: Axl is essential
for VEGF-A-dependent activation of PI3K/Akt. EMBO J. 31:1692–1703.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen CH, Lai JM, Chou TY, Chen CY, Su LJ,
Lee YC, Cheng TS, Hong YR, Chou CK, Whang-Peng J, et al: VEGFA
upregulates FLJ10540 and modulates migration and invasion of lung
cancer via PI3K/AKT pathway. PLoS One. 4:e50522009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Vachhani P and George S: VEGF inhibitors
in renal cell carcinoma. Clin Adv Hematol Oncol. 14:1016–1028.
2016.PubMed/NCBI
|
|
38
|
Comunanza V and Bussolino F: Therapy for
cancer: Strategy of combining anti-angiogenic and target therapies.
Front Cell Dev Biol. 5:1012017. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
An G, Liang S, Sheng C, Liu Y and Yao W:
Upregulation of microRNA-205 suppresses vascular endothelial growth
factor expression-mediated PI3K/Akt signaling transduction in human
keloid fibroblasts. Exp Biol Med. 242:275–285. 2017. View Article : Google Scholar
|
|
40
|
Zeng FC, Zeng MQ, Huang L, Li YL, Gao BM,
Chen JJ, Xue RZ and Tang ZY: Downregulation of VEGFA inhibits
proliferation, promotes apoptosis, and suppresses migration and
invasion of renal clear cell carcinoma. Onco Targets Ther.
9:2131–2141. 2016.PubMed/NCBI
|
|
41
|
Chen YS, Meng F, Li HL, Liu QH, Hou PF,
Bai J and Zheng JN: Dicer suppresses MMP-2-mediated invasion and
VEGFA-induced angiogenesis and serves as a promising prognostic
biomarker in human clear cell renal cell carcinoma. Oncotarget.
7:84299–84313. 2016.PubMed/NCBI
|
|
42
|
Fantozzi A, Gruber DC, Pisarsky L, Heck C,
Kunita A, Yilmaz M, Meyer-Schaller N, Cornille K, Hopfer U,
Bentires-Alj M and Christofori G: VEGF-mediated angiogenesis links
EMT-induced cancer stemness to tumor initiation. Cancer Res.
74:1566–1575. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gonzalez-Moreno O, Lecanda J, Green JE,
Segura V, Catena R, Serrano D and Calvo A: VEGF elicits
epithelial-mesenchymal transition (EMT) in prostate intraepithelial
neoplasia (PIN)-like cells via an autocrine loop. Exp Cell Res.
316:554–567. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Kim LC, Cook RS and Chen J: mTORC1 and
mTORC2 in cancer and the tumor microenvironment. Oncogene.
36:2191–2201. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Besharat ZM, Sabato C, Po A, Gianno F,
Abballe L, Napolitano M, Miele E, Giangaspero F, Vacca A, Catanzaro
G, et al: Low expression of miR-466f-3p sustains epithelial to
mesenchymal transition in Sonic hedgehog medulloblastoma stem cells
through Vegfa-Nrp2 signaling pathway. Front Pharmacol. 9:12812018.
View Article : Google Scholar : PubMed/NCBI
|
